ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
Market Cap
—
MomentumView details →
1D Return
—
YTD Return
—
RSI (14)
—
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
Market Cap
—
RSI (14)
—
MomentumView details →
1D Return
—
YTD Return
—
SummaryUpdated Jun 1, 2026
Alpha Cognition Inc. (NASDAQ:ACOG) is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Vancouver, Canada. The company was formerly known as Crystal Bridge Enterprises Inc. before changing its name in March 2021. Alpha Cognition focuses on developing treatments for neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company successfully transitioned from a pre-revenue clinical-stage entity to a commercial-stage company in 2025 with the launch of its flagship product ZUNVEYL for treating mild-to-moderate Alzheimer's disease.
Latest newsMore news →
Alpha Cognition reported second-quarter 2026 net product revenue of approximately $6 million from its Alzheimer's treatment ZUNVEYL, up about 71% sequentially from $3.5 million in the first quarter.23d agoAlpha Cognition Inc. received a European patent from the European Patent Office covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for treating mild-to-moderate Alzheimer's disease.38d ago